Abstract 4338: Enhancer mapping in triple negative breast cancer as a tool for biomarker and oncogene discovery

Triple Negative Breast Cancer (TNBC) represents a heterogeneous disease with no common drivers or effective targeted therapies. Here we use ChIP-Seq combined with RNA-Seq to map the gene-regulatory landscape of TNBC in cell lines and primary tumors. Using this approach we identify novel actionable subtypes of the disease based on enhancer activity. We also identify novel tumor-specific enhancers and associated enhancer-driven oncogenes, and confirm enhancer status as a predictive biomarker of gene dependency. Citation Format: Ryan Raisner, Russell Bainer, Karen Gascoigne. Enhancer mapping in triple negative breast cancer as a tool for biomarker and oncogene discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4338.